# An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

> **NCT03229252** · PHASE2 · COMPLETED · sponsor: **Spyryx Biosciences, Inc.** · enrollment: 91 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Placebo Inhalation Solution
- **DRUG:** SPX-101

## Key facts

- **NCT ID:** NCT03229252
- **Lead sponsor:** Spyryx Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-06-20
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229252, "An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03229252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*